Saint Louis University researchers are working across departments and around the world to create life-changing medications and biomedical devices.
Five of SLU鈥檚 researchers explain their work and the goals of SLU鈥檚 Institute for Drug and Biotherapeutic Innovation (SLU-IDBI).
Collaboration is Key
Researchers at SLU are in the midst of planning the Institute of Drug and Biotherapeutic Innovation (SLU-IDBI) to bring together experts in drug development to share expertise, stimulate ideas, and foster collaboration. These researchers create potential medications and biomedical devices for diseases that are oftentimes under-researched.
David Griggs, Ph.D, associate professor of molecular microbiology and immunology, is an example of one such researcher. Griggs researches diarrheal diseases.
鈥淸Diarrheal disease] kills between two and three million people per year,鈥 said Griggs. 鈥淥ver half of a million of those are children under the age of five.鈥
Griggs鈥 lab researches compounds that kill Cryptosporidium, a parasite that causes life-threatening diarrhea in infants. This impactful research garnered attention from the Bill and Melinda Gates Foundation and is now partially funded by the organization.
鈥淭he success of drug discovery really depends on successful collaborations,鈥 said Griggs.
SLU-IDBI is both an interdisciplinary collaboration and a global one. It consists of around 70 faculty members, and includes researchers from various departments at SLU including: Biomedical Engineering, Chemistry, Molecular Microbiology, and Pediatrics. Many of these faculty members have experience in the pharmaceutical industry, which brings a wealth of industry knowledge to the group. The researchers at SLU-IDBI also collaborate with researchers around the world to create transformative medications and devices.
A Focus on the Forgotten
鈥淲e came in here with the idea to really focus on what the big pharmaceutical companies
were not: rare diseases [and] neglected diseases which tend to afflict mostly people
in poor countries, and I think that fits very well with the mission of Saint Louis
University,鈥 said Griggs.
Diseases that mainly affect poorer countries, such as diarrheal diseases, are often less researched despite the fact that they are often more deadly. SLU-IDBI strives to address this disparity.
Adriana M. Monta帽o, Ph.D, associate professor of pediatrics, biochemistry, and molecular biology. studies Mucopolysaccharidosis (MPS). MPS is quite rare and found in children. 鈥淭he patients have skeletal abnormalities鈥 [and] have a very short life span,鈥 said Monta帽o.
Monta帽o developed an enzyme replacement therapy targeting MPS that is undergoing preclinical trials.
鈥淣ot so many people work on [orphan] diseases... we can make big changes,鈥 said Monta帽o.
Another promising project comes from the lab of Fran Sverdrup, Ph.D, associate professor of biochemistry and molecular biology. Sverdrup鈥檚 research focuses on facioscapulohumeral muscular dystrophy (FSHD) treatment.
Sverdrup began his research into FSHD shortly after he came to SLU, when his daughter was diagnosed with the disease.
鈥淭hat it鈥檚 a personal issue is tough. You have to find a pace that you can maintain, but every night I go home and I see my daughter and 鈥 that鈥檚 all it takes,鈥 said Sverdrup.
Though there are currently no treatments available for FSHD, Sverdrup鈥檚 lab has established a collaboration with a pharmaceutical partner and hopes to advance one of their treatments into human clinical trials soon.
Igniting Discovery
SLU-IDBI is also on the forefront of an entirely new drug delivery system.
Silviya Zustiak, Ph.D, associate professor of biomedical engineering, studies hydrogels, one of the newest entries into the market of drug delivery devices, Hydrogels are polymers that form ideal mimics of any soft tissue in the body and can house critical biologics. Zustiak explains that what differentiates the hydrogels that are being developed at SLU is that they 鈥渃an degrade in a desired amount of time.鈥
鈥淸These hydrogels] can cure diseases which previously have been thought incurable,鈥 said Zustiak.
Zustiak hopes that the innovative research happening at SLU will catalyze collaborations with companies who can then bring it to patients.
鈥淭he biotech scene in St. Louis is really attractive to our students and to our graduates,鈥 said Zustiak. 鈥淲e are creating a pipeline of problem solvers.鈥
St. Louis is rife with opportunity in this developing field, and with the Cortex Innovation Community just a few blocks away, SLU researchers are primed to make a big impact.
Founded in 2002 through a collaboration between SLU, Washington University in St. Louis, the University of Missouri - St. Louis, BJC Healthcare and the Missouri Botanical Garden, Cortex is the Midwest鈥檚 premier innovation hub for research, development, and commercialization in biosciences and technology. Because of Cortex, SLU-IDBI is able to connect and work with researchers both from the public sphere and from neighboring universities.
About the Faculty
Learn more about the researchers featured in this video and article.
David Griggs, Ph.D.
Associate Professor, Molecular Microbiology and ImmunologyGriggs鈥 research is currently focused on two different topics: 1) cell proteins called integrins effect on scar formation and 2) cryptosporidiosis, an illness that often causes life-threatening diarrhea. He hopes that the many collaborations that his lab and SLU鈥檚 IDBI engages in will spur the production of life-saving medications for rare and neglected diseases.
Marvin Meyers, Ph.D.
Associate Professor, Chemistry Program Coordinator, Chemical BiologyMeyers鈥 lab focuses on medicnical chemistry to 鈥渙ptimize the potency, pharmacokinetics, and safety profiles of compounds with the ultimate goal of identification of candidate drugs for clinical trials.鈥 His research specifically focused on finding new medications for infectious diseases. His lab is actively working on malaria, cryptosporidiosis, tuberculosis, herpes simplex virus, hepatitis B virus, and cryptococcal meningitis.
Adriana M. Monta帽o, Ph.D.
Associate Professor, Pediatrics & Biochemistry and Molecular Biology
Monta帽o researches enzyme replacement therapy, gene therapy and other types of treatment for mucopolysaccharidosis (MPS). She is specifically 鈥渨orking on developing a registry and growth charts for patients with MPS IVA and are in pre-clinical trials for enzyme replacement therapy for patients affected by MPS IVA.
Fran Sverdrup, Ph.D.
Associate Professor, Biochemistry and Molecular Biology
Sverdrup鈥檚 lab is 鈥渇ocused on drug discovery in human genetic diseases as well as infectious diseases鈥. His current research emphasis is on facioscapulohumeral muscular dystrophy (FSHD), which is one of the most common types of muscular dystrophy for which there is still no treatment for. His approach is to 鈥減erform high throughput screening of chemical libraries to identify compounds intended to epigenetically suppress the DUX4 gene.鈥
Silviya Zustiak, Ph.D.
Associate Professor, Biomedical Engineering
Zustiak鈥檚 research interests are hydrogels and tissue engineering. Her lab focuses on developing biomaterials as cell scaffolds for drug delivery purposes. She emphasizes that 鈥渂iomaterial-based models are crucial for bridging the gap between traditional tissue culture and animal models by providing a cell environment that closely mimics real tissue.鈥